|| List of recent Proteins-related patents
|Nucleic acid molecules encoding enzymes that confer disease resistance in jute|
The invention further relates to vectors, host cells, seeds, and plants comprising such a nucleic acid molecule. One aspect of the invention is an isolated antibody or antigen binding fragment thereof that specifically binds to a polypeptide molecule of the present invention.
|Polymers and plastics derived from animal proteins|
The invention is directed to a method for preparing a polymer derived from an animal protein, such as in a feedstock derived from animal by-products. The method involves hydrolyzing proteins present in a feedstock to obtain hydrolyzed proteins, wherein hydrolysis is conducted under conditions sufficient to digest the proteins and destroy pathogens; extracting a protein fraction from the hydrolyzed proteins; and treating the protein fraction with a crosslinking reagent to form the polymer.
|Method for preparing active form of tnfr-fc fusion protein|
The present invention relates to a method for separating and preparing a tnfr-fc fusion protein using hydrophobic interaction chromatography (hic). More particularly, the present invention relates to a method for separating and preparing a highly pure active protein from clipped proteins due to displacement effect by adjusting the conductivity of a protein sample using a high concentration of salt solution and by adjusting a loading amount thereof, and a tnfr-fc fusion protein prepared by the method..
|Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines|
This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (cppt), 1-cyanoimidazole (1-ci), 1-cyanobenzotriazole (1-cbt), or 2-cyanopyridazine-3(2h)one (2-cpo), or a functional derivative or modification thereof.
|Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines|
This invention provides novel reagents for cyanating polysaccharides in aqueous or part aqueous solutions so that they may be covalently linked to proteins either directly or through a spacer. These reagents include 1-cyano-4-pyrrolidinopyridinium tetrafluoroborate (cppt), 1-cyano-imidazole (1-ci), 1-cyanobenzotriazole (1-cbt), or 2-cyanopyridazine-3(2h)one (2-cpo), or a functional derivative or modification thereof.
|Activated collagen scaffold materials and their special fused active restoration factors|
Provided are activated collagen scaffold materials as well as their special fused active restoration factors useful for promoting tissue repair, such as bone damage repair or nerve injury repair. The special fused active restoration factors are fusion proteins comprising a collagen-binding domain (cbd) at n-/c-terminus of cytokines, wherein the collagen-binding domain is a polypeptide consisting of 7-27 amino acid residues with a conservative sequence shown in seq id no:12 at n-terminus.
|Use of prolyl hydroxylase inhibitors as a radioprotective drug for the lower gastrointestinal tract|
The present invention provides compositions and methods for treating or protecting mucosal tissues from damage associated with radiation and/or chemotherapy. Specifically, the instant invention is directed to inhibitors of prolyl hydroxylase domain (phd) proteins and the use of such inhibitors in treating or protecting the gastrointestinal tract from damage associated with radiation..
|Delivering functional nucleic acids to mammalian cells via bacterially-derived, intact minicells|
Intact bacterially derived minicells containing functional nucleic acids or plasmids encoding functional nucleic acids can reduce, in targeted mammalian cells, drug resistance, apoptosis resistance, and neoplasticity, respectively. Methodology that employs minicells to deliver functional nucleic acids, targeting the transcripts of proteins that contribute to drug resistance or apoptosis resistance, inter alia, can be combined with chemotherapy to increase the effectiveness of the chemotherapy..
|1,4- dihydropyridine derivatives with hsp modulating activity|
The invention provides 1,4-dihydropyridine derivatives of formula (i) wherein r1 is optionally substituted c6-24aryl group or 5 to 6 membered heteroaryl group comprising 1 to 3 nitrogen atoms or other heteroatoms like oxygen and sulphur, and combinations thereof; r2 and r3 are independently hydrogen or c1-6alkyl group; r4 and r5 are independently hydrogen, c1-6alkyl group optionally substituted with amino, mono- or di(c1-6alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional 1 to 3 n, o, s heteroatoms and optionally substituted with c1-6alkyl group or c1-6 alkoxy group; r6 is c1-6alkyl, c3-7cycloalkyl, c3-7cycloalkylc1-6alkyl or arylc1-6alkyl group; and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof for use in the therapeutic or prophylactic treatment of a disorder mediated by heat shock proteins.. .
|High-potency botulinum toxin formulations|
The present invention provides improved formulations of botulinum toxin that increase delivery of the botulinum toxin to neural and associated tissues and exhibit a higher specific neurotoxicity and higher potency (in ld50 units) than available formulations of botulinum toxins. These improved formulations enable physicians to treat a wide variety of pathological conditions with a lower toxin load that reduces the risk of inducing an immune response against the toxin and its associated proteins that may ultimately lead to the development of toxin resistance.
|Variant serum albumin with improved half-life and other properties|
The invention provides methods and materials for making and using variant serum albumin amino acid sequences which exhibit improved properties compared to wild type serum albumin sequences. The invention further provides methods and materials for making and using fusion proteins in which the variant serum albumin amino acid sequences are fused to a therapeutic or diagnostic agent, such as a therapeutic protein, or a functional fragment or variant thereof that maintains activity, and exhibits improved properties..
|Fusion proteins comprising pdgf and vegf binding portions and methods of using thereof|
The present provides fusion proteins comprising pdgf and vegf binding portions, and recombinant viral particles encoding the fusion proteins. Compositions comprising the fusion proteins and viral particles as well as methods of using the same are also provided..
|Novel bacillus thuringiensis gene with lepidopteran activity|
The invention provides nucleic acids, and variants and fragments thereof, obtained from strains of bacillus thuringiensis encoding polypeptides having pesticidal activity against insect pests, including lepidoptera. Particular embodiments of the invention provide isolated nucleic acids encoding pesticidal proteins, pesticidal compositions, dna constructs, and transformed microorganisms and plants comprising a nucleic acid of the embodiments.
|Methods and products for increasing frataxin levels and uses thereof|
Methods and products (e.g., recombinant proteins) are described for increasing frataxin expression/levels in a cell, as well as uses of such methods and products, for example for the treatment of friedreich ataxia in a subject suffering therefrom.. .
The present invention relates to reagents for separating proteins from detergent, reagents for detecting proteins in the presence of a detergent, and methods of using the same. The separating reagents contain a cyclic oligomer such as cyclodextrin and a cellulose derivative such as 2-hydroxyethyl cellulose.
|Filamentous fungi having an altered viscosity phenotype|
Described are compositions and methods relating to variant filamentous fungi having altered growth characteristics. Such variants are well-suited for growth in submerged cultures, e.g., for the large-scale production of enzymes and other proteins for commercial applications..
The invention provides a fusion protein comprising, from n-terminus to c-terminus: a) a first portion of a family b g-protein coupled receptor (gpcr) that comprises transmembrane helix (tm)-1, tm2 and tm3 of the gpcr; b) a stable protein domain; and c) a second portion of the gpcr comprising tm4, tm5, tm6 and tm7 of the gpcr. The invention also provides a method of crystallising a gpcr comprising providing the fusion protein of the invention and crystallising it to obtain crystals..
|Novel lipolytic enzyme lip2|
The present invention provides a novel nucleic acid sequence, designated lip2, encoding a lipolytic enzyme and the corresponding encoded amino acid sequences. The invention also provides expression vectors and host cells comprising a nucleic acid sequence encoding at least one novel lipolytic enzyme, recombinant lipolytic enzyme proteins and methods for producing the same..
|Novel cellulose and ligno-cellulose active proteins|
Methods to digest carbohydrates, especially lignocelluloses and hemicelluloses, using fungal proteins previously not recognized as having this activity are described.. .
|Activated collagen scaffold materials and their special fused active restoration factors|
Provided are activated collagen scaffold materials as well as their special fused active restoration factors useful for promoting tissue repair, such as bone damage repair or nerve injury repair. The special fused active restoration factors are fusion proteins comprising a collagen-binding domain (cbd) at n-/c-terminus of cytokines, wherein the collagen-binding domain is a polypeptide consisting of 7-27 amino acid residues with a conservative sequence shown in seq id no:4 at n-terminus.
|Expression cassette, use of the expression cassette, expression vector, prokaryotic host cell comprising expression vector, bacterial strain and a method for producing a polypeptide|
The subject matters of invention relate to expression cassette, use of the expression cassette, expression vector, prokaryotic host cell harbouring expression vector, bacterial strain, and method for producing a polypeptide. In more detail, the invention relate to stable expression of recombinant polypeptides, in systems with no need of using antibiotics.
|Composite sugar chain hydrolase|
The present invention provides a novel endo-β-n-acetylglucosaminidase (endo-om) using a transformant produced by cloning an endo-β-n-acetylglucosaminidase (endo-om) gene originated from a methylotrophic yeast ogataea minuta ifo10746 strain. The endo-om according to the present invention has a specific activity 13-fold higher than that of known endo-m and a vmax value 55-fold higher than that of the known endo-m, and is useful for the analysis of the structures of sugar chains, including complex type sugar chains, in glycoproteins and the modification of the sugar chains.
|Expression of biologically active proteins in a bacterial cell-free synthesis system using bacterial cells transformed to exhibit elevated levels of chaperone expression|
The present disclosure describes methods and systems for improving the expression of a properly folded, biologically active protein of interest in a cell free synthesis system. The methods and systems use a bacterial cell free extract having an active oxidative phosphorylation system, and include an exogenous protein chaperone.
|Cellular recognition conjugates and methods of use for the histological analysis of cancer tissue using maldi-ms imaging|
Disclosed are conjugates that can bind to one or more site on cancer cell surface, for example, surface proteins, compound specific receptors and carbohydrates that comprise the surface of specific cell types. The disclosed conjugates can thereby serve as indicators identifying the presence of cancerous tissue..
|Alpha toxin detection of gpi anchored proteins|
The present invention relates to a method for the purification, concentration and identification of glycosylphosphatidylinositol anchored proteins (gpi-aps) from a biological sample (cells, tissues and/or blood/serum) in a patient or subject, including a human patient or subject. A new method to separate gpi-anchored glycoproteins, a class of glycoproteins found in all animal cells and fluids including serum, from other glycoproteins and proteins for the purpose of identifying potential biomarkers for various diseases, including cancer, especially breast cancer, vaginal cancer, endometrial cancer, uterine cancer, cervical cancer, pancreatic cancer and prostate cancer.
|Method for exosomal biomarker detection by electric field-induced release and measurement|
The molecules harbored in exosomes play important roles in biological science. A highly desirable goal for exosome research is the rapid, simple, simultaneous tracking and quantification of exosome harbored molecules.
|Industrial method for preparing alkaline hydrolysates of vegetable proteins|
A method for preparing alkaline hydrolysates of vegetable proteins, includes the following steps: 1) placing the vegetable proteins in suspension in water so as to have a concentration of 15 to 30 dry weight %, at a temperature of 70 to 80° c. And a ph of 9.5 to 10.5 by adding an alkaline hydroxide selected from the group made up of sodium hydroxide and potassium hydroxide; 2) allowing the suspension to incubate for 10 to 15 hours, at a temperature of 70 to 80° c.
|Transgenic plants expressing civps or intein modified proteins and related method|
Transgenic plants that express civps or intein modified proteins, compositions of matter comprising them, products of diverse applications made from the transgenic plants, methods to construct the transgenic plants containing civps or intein modified genes, methods to express civps or intein modified proteins in plants, and methods of using the transgenic plants.. .
|Microspheres for controlled- or sustained-release delivery of therapeutics|
A new microsphere formulation (composition) for controlled- or sustained-release delivery of therapeutic ingredient(s), mainly peptides and proteins not over 10k in molecular weight, comprises at least a therapeutic ingredient, a helping agent (such as ph sensitive agent whose solubility is a function of ph) and a biodegradable polymer. The therapeutic ingredient(s) and the helping agent are in the form of fine particles, less than 1o um in diameter, encapsulated in the polymer which forms the microsphere matrix.
|Novel compositions and methods|
The present invention is directed to a polypeptide which comprises: (i) an rv2386c protein sequence; (ii) a variant of an rv2386c protein sequence; of (iii) an immunogenic fragment of an rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis..
|Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose|
Lower eukaryotic host cells have been engineered to produce glycoprotein having at least one terminal α-galactosyl epitope. The glycoproteins are useful for the production of highly antigenic glycoprotein compositions with advantages for the production of vaccines..
|Kidney disease targets and uses thereof|
The present invention provides a method for diagnosing and detecting diseases associated with kidney. The present invention provides one or more proteins or fragments thereof, peptides or nucleic acid molecules differentially expressed in kidney diseases (kcat) and antibodies binds to kcats.
|Neutralizing antibodies and methods of use thereof|
This invention provides monoclonal antibodies that recognize the toll-like receptor 4/md-2 receptor complex, and monoclonal antibodies that recognize the tlr4/md2 complex as well as tlr4 when not complexed with md-2. The invention further provides methods of using the humanized monoclonal antibodies as therapeutics.
|Mig-7 as a specific anticancer target|
Aspects of the present invention provide novel mig-7 encoding nucleic acids and mig-7 polypeptides, recombinant dna expression systems and host cells containing same, as well as methods of inhibiting expression of the subject nucleic acid molecules, inhibiting production of the encoded proteins or polypeptides, inhibiting metastasis of a carcinoma cell in a subject (including in humans), inhibiting migration/invasion of and mimicking of normal cells by carcinoma cells in a subject, detecting the presence of a cancer cell (e.g., a migrating/invading cancer cell or carcinoma cell mimic, and tumor neovascularization) in a sample of a subject's tissue or body fluids, and inhibiting the migration/invasion of or endothelial cell mimicking by a placental cell into the blood stream or vessels of a female mammal. Particular aspects relate to novel anti-mig-7 antibodies, diagnostic and/or prognostic methods, and therapeutic methods comprising use of the inventive nucleic acids, polypeptides and antibodies or derivatives thereof..
|Methods to control protein heterogeneity|
The instant invention relates to the field of protein production and in particular to controlled protein heterogeneity compositions and processes for controlling the heterogeneity of proteins expressed in host cells.. .
|Amino acid sequences directed against il-17a, il-17f and/or il17-a/f and polypeptides comprising the same|
The present disclosure relates to amino acid sequences that are directed against (as defined herein) any of il-17a, il-17f and/or il-17a/f including combinations thereof, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.. .
|Protease-deficient bacillus anthracis|
The invention relates to a bacillus anthracis (b. Anthracis) in which more than one secreted protease is inactivated by genetic modification.
|Il-22 polypeptides and il-22 fc fusion proteins and methods of use|
The invention relates to il-22 polypeptides, il-22 fc fusion proteins and il-22 agonists, composition comprising the same, methods of making and methods of using the composition for the treatment of diseases. The invention also relates to il-22 receptor associated reagents and methods of use thereof..
|Methods of treating epidermal growth factor deletion mutant viii related disorders|
The present invention relates to methods of treating treating epidermal growth factor deletion mutant viii (egfrviii) related disorders, such as glioblastoma or anaplastic astrocyte tumors, using antigen binding proteins, including antibodies against egfrviii conjugated to a drug. Diagnostic and therapeutic formulations of such antibodies and drug conjugates thereof are also provided..
|Targeted carriers for drug delivery across the gastrointestinal epithelium|
A system and method for transcellular transport of compositions containing agents (e.g., research, analytical, reporter or molecular probes, diagnostic and therapeutic agents, biologically active agents, research agents, analytical agents, imaging agents, monitoring agents, enzymes, proteins, peptides, nucleic acids, lipids, sugars, hormones, lipoproteins, chemicals, viruses, bacteria, cells, including modified cells, biosensors, markers, antibodies and/or ligands) across the gastrointestinal epithelial layer including use of a composition containing the agent and a targeting moiety, specific for a determinant at the target location. An exemplary composition of the system includes an anti-icam antibody targeting moiety, specific for targeting icam-1.
|Method to realize electronic field-effect transistor sensors|
A transistor includes at least one conductive layer, at least one gate dielectric layer and at least one semiconducting film deposited on top of a receptor molecule layer previously deposited or covalently linked to the surface of the gate dielectric. The layer of biological material includes single or double layers of phospholipids, layers made of proteins such as receptors, antibodies, ionic channels and enzymes, single or double layers of phospholipids with inclusion or anchoring of proteins such as: receptors, antibodies, ionic channels and enzymes, layers made of oligonucleotide (dna, rna, pna) probes, layers made of cells or viruses, layers made of synthetic receptors for example molecules or macromolecules similar to biological receptors for properties, reactivity or steric aspects..
Disclosed herein is a protein standard for gel electrophoresis. The standard may be detected using multiple modalities.
|Native protein electrophoresis and methods of use|
A method of characterizing proteins has been developed that includes providing a sample that contains a plurality of proteins to be characterized, wherein at least a first protein of the plurality of proteins is in its native form. Additionally, the method includes contacting the sample containing the plurality of proteins with a solution to form a sample solution, and then contacting the sample solution with a gel.
|Increasing the molar mass of polyalkylenepolyamines by homogeneously catalyzed alcohol amination|
Process for increasing the molar mass of polyalkylenepolyamines by homogeneously catalyzed alcohol amination, which comprises carrying out a reaction of the polyalkylenepolyamines in a reactor with elimination of water in the presence of a homogeneous catalyst and removing the water of reaction from the reaction system. Polyalkylenepolyamines obtainable by such processes, and polyalkylenepolyamines comprising hydroxyl groups, secondary amines or tertiary amines.
|Sialic acid derivatives|
An amine or hydrazide derivative of a sialic acid unit, e.g. In a polysaccharide, is reacted with a bifunctional reagent at least one of the functionalities of which is an ester of n-hydroxy succinimide, to form an amide or hydrazide product.
|Mutations of histone proteins associated with proliferative disorders|
The present application shows the relationship between variations in the amino acid sequence of histone proteins, more specifically the h3.3 protein, and proliferation-associated disorders. Herewith provided are predictive methods, commercial packages, therapeutic methods and screening methods based on this relationship..
|Small molecules that promote skin regeneration|
Provided herein are small molecules for the induction of fibroblast proliferation and increased secretion or production of proteins. The small molecules described herein can be used for the promotion of skin regeneration.
|Modified peptides and proteins|
Provided are compounds and methods of making compounds containing two or three groups derived from a peptide, such as enfuvirtide or exenatide, covalently bound to a linker. The compounds may contain polyethylene glycol groups to enhance solubility and pharmacokinetic properties.
|Fibronectin based scaffold domain proteins that bind to myostatin|
The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, copd, chronic kidney disease, heart failure, myocardial infarction, and fibrosis.
|Compositions of active wnt protein|
Compositions of purified biologically active wnt proteins are provided. Wnt proteins are found to be hydrophobic and post-translationally modified by addition of a lipid moiety at a conserved cysteine residue.
|Proteins with repetitive bacterial-ig-like (big) domains present in leptospira species|
The invention relates to three isolated dna molecules that encode for proteins, bigl1, bigl2 and bigl3, in the leptospira sp bacterium which have repetitive bacterial-ig-like (big) domains and their use in diagnostic, therapeutic and vaccine applications. According to the present invention, the isolated molecules encoding for bigl1, bigl2 and bigl3 proteins are used for the diagnosis and prevention of infection with leptospira species that are capable of producing disease in humans and other mammals, including those of veterinary importance..
|Novel method of protein purification|
The present disclosure provides methods for releasing intracellular proteins. The method allows isolation of the protein of interest from the cell without the requirement for mechanical disruption of the cells, without the need for isolation of the cells from the culture media, and without the need for removal of the cells from the culture media..
|Yeast expressing saccharolytic enzymes for consolidated bioprocessing using starch and cellulose|
The present invention is directed to a yeast strain, or strains, secreting a full suite, or any subset of that full suite, of enzymes to hydrolyze corn starch, corn fiber, lignocellulose, (including enzymes that hydrolyze linkages in cellulose, hemicellulose, and between lignin and carbohydrates) and to utilize pentose sugars (xylose and arabinose). The invention is also directed to the set of proteins that are well expressed in yeast for each category of enzymatic activity.
|Mammalian cell lines for increasing longevity and protein yield from a cell culture|
Disclosed are compositions and methods for increasing the longevity of a cell culture and permitting the increased production of proteins, preferably recombinant proteins, such as antibodies, peptides, enzymes, growth factors, interleukins, interferons, hormones, and vaccines. Cells transfected with an apoptosis-inhibiting gene or vector, such as a triple mutant bcl-2 gene, can survive longer in culture, resulting in extension of the state and yield of protein biosynthesis.
|Yeast recombinant cell capable of producing gdp-fucose|
A yeast strain expressing a bi-functional fucokinase/gdp-l-fucose pyrophosphorylase enzyme and capable of producing gdp-l-fucose in vivo is provided. Also provided are yeast cells which express a gdp-l-fucose transporter and/or a fucosyl transferase with the bi-functional enzyme.
|Yeast artificial chromosome carrying the mammalian glycosylation pathway|
A yeast artificial chromosome (yac) directing the expression of one or more activities of the humanized glycosylation pathway is provided. The said yac comprises one or more expression cassettes for fusion proteins of heterologous glycosylation pathway and an er/golgi retention sequence.
|Graphene-biomolecule bioelectronic devices|
Provided are devices and methods featuring a nanoelectronic interface between graphene devices (for example, field effect transistors or fets) and biomolecules such as proteins, which in turn provides a pathway for production of bioelectronic devices that combine functionalities of the biomolecular and inorganic components. In one exemplary application, one may functionalize graphene fets with fluorescent proteins to yield hybrids that respond to light at wavelengths defined by the optical absorption spectrum of the protein.
|Sensors employing single-walled carbon nanotubes|
Sensing compositions, sensing element, sensing systems and sensing devices for the detection and/or quantitation of one or more analytes. Compositions comprising carbon nanotubes in which the carbon nanotubes retain their ability to luminesce and in which that luminescence is rendered selectively sensitive to the presence of an analyte.
|Proteins and method for detection of lyme disease|
Recombinant b. Burgdorferi proteins, representative of the life cycle, are membrane-immobilized to capture antibodies in biological samples.
|Citrullinated proteins: a post-translated modification of myocardial proteins as marker of physiological and pathological disease|
Disclosed herein are methods for diagnosing cardiovascular disease. The methods comprise detection of citrullinated proteins..
|Liquid to liquid biological particle concentrator|
A rapid one-pass liquid filtration system efficiently concentrates biological particles that are suspended in liquid from a dilute feed suspension. A sample concentrate or retentate suspension is retained while eliminating the separated fluid in a separate flow stream.
|Method for selectively inhibiting acat1 in the treatment of neurodegenerative diseases|
The present invention features methods for stimulating clearance of misfolded or aggregated proteins or peptides in microglia, and treating neurodegenerative diseases associated with such pathology in brain by selectively inhibiting the expression or activity of acyl-coa:cholesterol acyltransferase 1, but not acyl-coa:cholesterol acyltransferase 2.. .
|Compositions and methods for treatment of cytomegalovirus|
The present disclosure provides compositions and methods useful for treating hcmv infection. As described herein, the compositions and methods are based on development of immunogenic compositions that include virus-like particles (vlps) which comprise one or more moloney murine leukemia virus (mmlv) core proteins and include one or more hcmv epitopes, such as, for example, from hcmv envelope glycoproteins gb and/or gh and/or tegument protein pp65.
|Adult stem cells/progenitor cells and stem cell proteins for treatment of eye injuries and diseases|
The present invention encompasses methods and compositions for treating an ocular disease, disorder or condition in a mammal. The invention includes a population of mesenchymal stromal cells that possess anti-inflammatory, anti-apoptotic, immune modulatory and anti-tumorigenic properties.
Embodiments concern constructs comprising surrogate light chain sequences. In particular, embodiments concern constructs that can bind to erbb3 and aspects relating to such constructs..
|Dual variable domain immunoglobulins and uses thereof|
The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.. .
|Vegf analogs and methods of use|
Modified vegf proteins that inhibit vegf-mediated activation or proliferation of endothelial cells are disclosed. The analogs may be used to inhibit vegf-mediated activation of endothelial cells in angiogenesis-associated diseases such as cancer, inflammatory diseases, eye diseases, and skin disorders..
|Mitochondrial proteins constructs and uses thereof|
The invention provides fusion protein constructs comprising a functional mitochondrial protein and methods of treating mitochondrial disorders by the fusion proteins and compositions thereof.. .
|Vectors conditionally expressing protein|
This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing one or more proteins under the control of a gene expression modulation, system in the presence of activating ligand and uses for therapeutic purposes in animals.
|Use of inclusion bodies as therapeutic agents|
The present invention relates to the use of inclusion bodies as vehicles for therapeutic protein delivery. This method is applicable to the delivery of therapeutic proteins to intracellular locations.
The present disclosure relates to a soluble cd52 glycoprotein and its use in treating diseases regulated by effector t-cells, for example autoimmune diseases such as type 1 diabetes. The present disclosure also relates to fusion proteins comprising the soluble glycoprotein, to cells expressing high levels of cd52, and to diagnostic methods based on the detection of cd52 expression levels in a subject..
|Fc receptor binding proteins|
The disclosure relates to antibodies that bind fcrn and methods of using these antibodies.. .